Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines.

NPJ vaccines·2026
Same author

Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves.

Circulation. Cardiovascular interventions·2026
Same author

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Nature communications·2025
Same author

Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States.

JACC. Cardiovascular interventions·2025
Same author

The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells <i>in vitro</i> and <i>in vivo</i>.

Oncotarget·2025
Same author

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians.

CA: a cancer journal for clinicians·2025

Related Experiment Video

Updated: Jun 6, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K

Systemic Therapy for Hepatocellular Carcinoma.

Emily Kinsey1, Michael A Morse2

  • 1Department of Medicine, Division of Hematology, Oncology & Palliative Care, VCU Health, Richmond, VA, USA.

Clinics in Liver Disease
|November 28, 2024
PubMed
Summary

Systemic therapy for hepatocellular carcinoma now includes immune checkpoint inhibitors. Future treatments focus on adjuvant settings and patients with advanced liver dysfunction.

Keywords:
AtezolizumabBevacizumabCabozantinibDurvalumabIpilimumabLenvatinibNivolumabTremelimumab

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

385

Related Experiment Videos

Last Updated: Jun 6, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

385

Area of Science:

  • Hepatobiliary cancers
  • Medical oncology
  • Immunotherapy

Background:

  • Hepatocellular carcinoma (HCC) systemic therapy has advanced significantly.
  • Initial treatments like sorafenib have been surpassed by newer options.
  • Current standards include immune checkpoint inhibitors (ICIs).

Purpose of the Study:

  • To review the evolution of systemic therapy for hepatocellular carcinoma.
  • To highlight current treatment standards and emerging therapeutic strategies.
  • To discuss future directions in HCC treatment research.

Main Methods:

  • Literature review of systemic therapies for hepatocellular carcinoma.
  • Analysis of current clinical trial data and treatment guidelines.
  • Identification of ongoing and future research areas.

Main Results:

  • First-line therapy has shifted to ICI combinations (atezolizumab/bevacizumab, durvalumab/tremelimumab).
  • Upcoming therapies include camrelizumab/rivoceranib and nivolumab/ipilimumab.
  • Second-line options remain multikinase inhibitors or ramucirumab.

Conclusions:

  • Immune checkpoint blockade is the new standard for first-line HCC treatment.
  • Research is expanding to adjuvant settings and patients with Child-Pugh B liver function.
  • Novel checkpoint molecules and combination strategies are under investigation.